Serious ill effects have not been reported following acute ingestion of large doses of progestin/estrogen-containing oral contraceptives by young children. Overdosage of estrogen may cause nausea and vomiting, and withdrawal bleeding may occur.

femhrt (norethindrone acetate, ethinyl estradiol) should not be used in women with any of the following conditions:

1. Undiagnosed abnormal genital bleeding.
2. Known, suspected, or history of cancer of the breast.
3. Known or suspected estrogen-dependent neoplasia.
4. Active of deep vein thrombosis, pulmonary embolism or history of these conditions.
5. Active or recent (e.g., within past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).
6. Liver dysfunction or disease.
7. femhrt (norethindrone acetate, ethinyl estradiol) should not be used in patients with known hypersensitivity to its ingredients.
8. Known or suspected pregnancy. There is no indication for femhrt (norethindrone acetate, ethinyl estradiol) in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See PRECAUTIONS.)

Last reviewed on RxList: 1/23/2009
This monograph has been modified to include the generic and brand name in many instances.